4/A: Ionis Pharma EVP Amends Stock Transaction Report

Ionis Pharmaceuticals' EVP, Chief Development Officer, Richard S. Geary, filed an amended Form 4 to correct previously reported stock option exercises and sales.

Summary

• Richard S. Geary, Executive Vice President and Chief Development Officer of Ionis Pharmaceuticals, Inc., filed an amended Form 4 to correct the amount of shares acquired and disposed of in transactions reported on November 3, 2025.
• On November 3, 2025, Mr. Geary exercised non-qualified stock options to acquire 775 shares of Common Stock at an exercise price of $60.89 per share.
• Concurrently on November 3, 2025, Mr. Geary sold 775 shares of Common Stock at a weighted average price of $75.054 per share, with individual sales ranging from $75.00 to $75.25.
• Also on November 3, 2025, Mr. Geary exercised non-qualified stock options to acquire 905 shares of Common Stock at an exercise price of $56.78 per share.
• Simultaneously on November 3, 2025, Mr. Geary sold 905 shares of Common Stock at a weighted average price of $75.054 per share, with individual sales ranging from $75.00 to $75.25.
• Following these reported transactions, Mr. Geary directly beneficially owns 59,657 shares of Common Stock.
• Mr. Geary also holds derivative securities, including a non-qualified stock option to buy 15,538 shares at $56.78 and another to buy 19,101 shares at $60.89.

Sentiment

Score: 5

Explanation: The filing is a routine insider transaction report with a correction, indicating neither strong positive nor negative sentiment for the company's operational performance or future prospects.

Positives

• The executive's sale price of $75.054 per share is notably higher than the exercise prices of $60.89 and $56.78, indicating a profitable monetization of stock options.

Negatives

• The sale of shares by an executive, even following an option exercise, can sometimes be perceived as a reduction in direct equity exposure, though it is a common practice for liquidity and diversification.

Industry Context

This filing is a routine disclosure of an insider's stock transactions and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive stock ownership and trading activity, which is a standard regulatory disclosure.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Trading, Stock Option Exercise, Stock Sale, Beneficial Ownership, Richard S. Geary, SEC Filing